248 related articles for article (PubMed ID: 32637297)
1. Brain iron deposition after Ferumoxytol-enhanced MRI: A study of Porcine Brains.
Theruvath AJ; Aghighi M; Iv M; Nejadnik H; Lavezo J; Pisani LJ; Daldrup-Link HE
Nanotheranostics; 2020; 4(4):195-200. PubMed ID: 32637297
[TBL] [Abstract][Full Text] [Related]
2. Brain Iron Assessment after Ferumoxytol-enhanced MRI in Children and Young Adults with Arteriovenous Malformations: A Case-Control Study.
Iv M; Ng NN; Nair S; Zhang Y; Lavezo J; Cheshier SH; Holdsworth SJ; Moseley ME; Rosenberg J; Grant GA; Yeom KW
Radiology; 2020 Nov; 297(2):438-446. PubMed ID: 32930651
[TBL] [Abstract][Full Text] [Related]
3. Ferumoxytol Does Not Impact Standardized Uptake Values on PET/MR Scans.
Muehe AM; Yerneni K; Theruvath AJ; Thakor AS; Pribnow A; Avedian R; Steffner R; Rosenberg J; Hawk KE; Daldrup-Link HE
Mol Imaging Biol; 2020 Jun; 22(3):722-729. PubMed ID: 31325083
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Three Ultrasmall, Superparamagnetic Iron Oxide Nanoparticles for MRI at 3.0 T.
Colbert CM; Ming Z; Pogosyan A; Finn JP; Nguyen KL
J Magn Reson Imaging; 2023 Jun; 57(6):1819-1829. PubMed ID: 36250695
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI.
Muehe AM; Siedek F; Theruvath AJ; Seekins J; Spunt SL; Pribnow A; Hazard FK; Liang T; Daldrup-Link H
Theranostics; 2020; 10(8):3612-3621. PubMed ID: 32206111
[TBL] [Abstract][Full Text] [Related]
6. Ferumoxytol-enhanced magnetic resonance imaging methodology and normal values at 1.5 and 3T.
Stirrat CG; Alam SR; MacGillivray TJ; Gray CD; Forsythe R; Dweck MR; Payne JR; Prasad SK; Petrie MC; Gardner RS; Mirsadraee S; Henriksen PA; Newby DE; Semple SI
J Cardiovasc Magn Reson; 2016 Jul; 18(1):46. PubMed ID: 27465647
[TBL] [Abstract][Full Text] [Related]
7. Imaging behavior of the normal adrenal on ferumoxytol-enhanced MRI: preliminary findings.
Gunn AJ; Seethamraju RT; Hedgire S; Elmi A; Daniels GH; Harisinghani MG
AJR Am J Roentgenol; 2013 Jul; 201(1):117-21. PubMed ID: 23789664
[TBL] [Abstract][Full Text] [Related]
8. How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol.
Daldrup-Link HE; Theruvath AJ; Rashidi A; Iv M; Majzner RG; Spunt SL; Goodman S; Moseley M
Pediatr Radiol; 2022 Feb; 52(2):354-366. PubMed ID: 34046709
[TBL] [Abstract][Full Text] [Related]
9. MRI assessment of hepatic iron clearance rates after USPIO administration in healthy adults.
Storey P; Lim RP; Chandarana H; Rosenkrantz AB; Kim D; Stoffel DR; Lee VS
Invest Radiol; 2012 Dec; 47(12):717-24. PubMed ID: 23070094
[TBL] [Abstract][Full Text] [Related]
10. Ultrasmall superparamagnetic iron-oxide-enhanced MR imaging of normal bone marrow in rodents: original research original research.
Simon GH; Raatschen HJ; Wendland MF; von Vopelius-Feldt J; Fu Y; Chen MH; Daldrup-Link HE
Acad Radiol; 2005 Sep; 12(9):1190-7. PubMed ID: 16099684
[TBL] [Abstract][Full Text] [Related]
11. Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific.
McConnell HL; Schwartz DL; Richardson BE; Woltjer RL; Muldoon LL; Neuwelt EA
Nanomedicine; 2016 Aug; 12(6):1535-42. PubMed ID: 27071335
[TBL] [Abstract][Full Text] [Related]
12. Incidental ferumoxytol artifacts in clinical brain MR imaging.
Bowser BA; Campeau NG; Carr CM; Diehn FE; McDonald JS; Miller GM; Kaufmann TJ
Neuroradiology; 2016 Nov; 58(11):1087-1091. PubMed ID: 27704163
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of ultrasmall superparamagnetic iron-oxide (USPIO) enhanced MRI with ferumoxytol to quantify arterial wall inflammation.
Smits LP; Tiessens F; Zheng KH; Stroes ES; Nederveen AJ; Coolen BF
Atherosclerosis; 2017 Aug; 263():211-218. PubMed ID: 28662398
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging of experimental atherosclerotic plaque: comparison of two ultrasmall superparamagnetic particles of iron oxide.
Herborn CU; Vogt FM; Lauenstein TC; Dirsch O; Corot C; Robert P; Ruehm SG
J Magn Reson Imaging; 2006 Aug; 24(2):388-93. PubMed ID: 16791857
[TBL] [Abstract][Full Text] [Related]
15. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
[TBL] [Abstract][Full Text] [Related]
16. Measurement of microvascular cerebral blood volume changes over the cardiac cycle with ferumoxytol-enhanced T
Rivera-Rivera LA; Johnson KM; Turski PA; Wieben O; Schubert T
Magn Reson Med; 2019 Jun; 81(6):3588-3598. PubMed ID: 30756424
[TBL] [Abstract][Full Text] [Related]
17. A comparison of ferumoxytol with gadolinium as contrast agents for the diagnostic magnetic resonance imaging of osteomyelitis.
Langsjoen J; Neuwelt A; Eberhardt S; Mlady G; Shukla U; Murali S; Pizanis C; Sillerud LO
Magn Reson Imaging; 2020 Sep; 71():45-54. PubMed ID: 32439428
[TBL] [Abstract][Full Text] [Related]
18. Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice.
Serkova NJ; Renner B; Larsen BA; Stoldt CR; Hasebroock KM; Bradshaw-Pierce EL; Holers VM; Thurman JM
Radiology; 2010 May; 255(2):517-26. PubMed ID: 20332377
[TBL] [Abstract][Full Text] [Related]
19. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study.
Neuwelt EA; Várallyay CG; Manninger S; Solymosi D; Haluska M; Hunt MA; Nesbit G; Stevens A; Jerosch-Herold M; Jacobs PM; Hoffman JM
Neurosurgery; 2007 Apr; 60(4):601-11; discussion 611-2. PubMed ID: 17415196
[TBL] [Abstract][Full Text] [Related]
20. Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.
Barajas RF; Hamilton BE; Schwartz D; McConnell HL; Pettersson DR; Horvath A; Szidonya L; Varallyay CG; Firkins J; Jaboin JJ; Kubicky CD; Raslan AM; Dogan A; Cetas JS; Ciporen J; Han SJ; Ambady P; Muldoon LL; Woltjer R; Rooney WD; Neuwelt EA
Neuro Oncol; 2019 Mar; 21(4):517-526. PubMed ID: 30277536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
